Winn-Dixie completes roll out of Food Recovery Program
JACKSONVILLE, Fla. Winn-Dixie has completed its rollout of a program that provides perishable items to local Feeding America affiliate food banks in the company’s five-state operating area.
Winn-Dixie said that approximately 3.5 million pounds of usable food was donated to feed the hungry in its Food Recovery Program’s pilot phase during the past 15 months
“As a grocer, we are concerned about the number of Americans seeking food assistance in today’s economy, and we are very pleased to be a part of the solution,” said Mary Kellmanson, group VP marketing for Winn-Dixie. “Our partnership with Feeding America and its network of food banks is making a meaningful impact in the fight against hunger.”
Winn-Dixie first piloted the program in ten stores beginning in January 2009, and has quietly expanded it throughout its operating area. It will be rolled out to all of its 515 stores by the end of April. Average donations of usable food in similar programs across the country range between 250 and 300 pounds each week per store, including foods like bread, meats, cheeses, bagged fruits and vegetables, gelatin desserts and sandwiches. Winn-Dixie officials estimate the program will result in 6 million to 8 million pounds of usable food making its way to food banks each year once the program is operating in all of the company’s stores.
FDA committee won’t recommend approval for non-Hodgkin’s lymphoma treatment
GAITHERSBURG, Md. A Food and Drug Administration advisory committee declined to recommend approval for a cancer drug made by Cell Therapeutics, the company announced Monday.
Cell Therapeutics said the FDA’s Oncologic Drugs Advisory Committee voted unanimously that data from clinical trials of pixantrone, a treatment for non-Hodgkin’s lymphoma, did not support its approval. Pixantrone would have been the first drug to treat relapsed or refractory NHL in patients who had received two or more prior therapies.
The FDA is not bound by the recommendations of advisory committees, and the agency is expected to decide whether or not to approve pixantrone on April 23. It does, however, take the recommendations into account when deciding whether or not to approve a drug, and the committee’s vote will likely diminish pixantrone’s chances for winning approval.
Merck KGaA suspends cancer vaccine trial
DARMSTADT, Germany A mid-stage clinical trial program to investigate a Merck KGaA cancer vaccine has been put on hold due to patients’ experiencing adverse side effects, the German drug maker announced Tuesday.
Merck KGaA, which is separate from the U.S.-based Merck & Co. and operates in the United States under the name EMD, said it temporarily suspended recruitment and treatment of patients in the phase 2 trial for Stimuvax (BLP25 liposome vaccine) after a patient with the bone marrow cancer multiple myeloma developed encephalitis. Merck said it made its decision under in alignment with a Food and Drug Administration hold placed on its investigational new drug application for Stimuvax.
The patient who developed encephalitis, a potentially fatal inflammation of the brain, was in an experimental arm of the clinical program and taking Stimuvax in combination with low doses of the cancer drug cyclophosphamide, which was not used in the other Stimuvax studies.
Another program, a phase 3 trial involving patients with non-small cell lung cancer and breast cancer, is affected as well, though Merck did not say exactly how.